早期肝细胞癌患者射频消融后辅助钬-166放射性栓塞:剂量探索研究(HORA EST HCC试验)
这项多中心前瞻性剂量递增研究纳入12例BCLC早期肝细胞癌(2-5 cm)患者,射频消融后5-10天行(超)选择性钬-166微球输注,按治疗体积剂量60 Gy、90 Gy、120 Gy递增。治疗体积剂量90 Gy时达到主要终点,靶体积中位吸收剂量138 Gy,1年随访未见局部复发。
要点
- 射频消融后辅助(超)选择性钬-166微球输注,治疗体积剂量90 Gy可达到主要终点。
- 90 Gy队列靶体积中位吸收剂量138 Gy(IQR 127-145),满足≥120 Gy要求。
- 1年随访内未发现局部复发。
核心结论
- 射频消融后辅助(超)选择性钬-166微球输注治疗肝细胞癌,治疗体积剂量90 Gy可安全给药,同时靶体积达到≥120 Gy,可能为2-5 cm肝细胞癌病灶的有利辅助治疗。
研究设计与样本
- 多中心、前瞻性剂量递增研究,纳入BCLC早期肝细胞癌且病灶2-5 cm的患者。
- 射频消融后第5-10天行(超)选择性钬-166微球输注,治疗体积剂量按60 Gy、90 Gy、120 Gy递增,每队列最多10例。
- 剂量分布基于SPECT-CT,主要终点为队列内9/10例患者靶体积剂量≥120 Gy。
主要发现
- 共治疗12例患者(男性10例),中位年龄66.5岁(IQR 64.3-71.7),中位肿瘤直径2.7 cm(IQR 2.1-4.0)。
- 治疗体积吸收剂量90 Gy时达到主要终点,靶体积中位吸收剂量138 Gy(IQR 127-145)。
- 1年随访内未发现局部复发。
关键数值与推荐
- 主要终点为队列内9/10例患者靶体积吸收剂量≥120 Gy。
- 治疗体积剂量90 Gy时达到主要终点,靶体积中位吸收剂量138 Gy(IQR 127-145)。
临床怎么用
- 原文结论认为,射频消融后辅助(超)选择性钬-166微球输注治疗肝细胞癌,治疗体积剂量90 Gy可安全给药,且靶体积可达≥120 Gy,可能为2-5 cm肝细胞癌病灶的有利辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to investigate the biodistribution of (super-)selective trans-arterial radioembolization (TARE) with holmium-166 microspheres (166Ho-MS), when administered as adjuvant therapy after RFA of HCC 2-5 cm. The objective was to establish a treatment volume absorbed dose that results in an absorbed dose of ≥ 120 Gy on the hyperemic zone around the ablation necrosis (i.e., target volume). METHODS: In this multicenter, prospective dose-escalation study in BCLC early stage HCC patients with lesions 2-5 cm, RFA was followed by (super-)selective infusion of 166Ho-MS on day 5-10 after RFA. Dose distribution within the treatment volume was based on SPECT-CT. Cohorts of up to 10 patients were treated with an incremental dose (60 Gy, 90 Gy, 120 Gy) of 166Ho-MS to the treatment volume. The primary endpoint was to obtain a target volume dose of ≥ 120 Gy in 9/10 patients within a cohort. RESULTS: Twelve patients were treated (male 10; median age, 66.5 years (IQR, [64.3-71.7])) with a median tumor diameter of 2.7 cm (IQR, [2.1-4.0]). At a treatment volume absorbed dose of 90 Gy, the primary endpoint was met with a median absorbed target volume dose of 138 Gy (IQR, [127-145]). No local recurrences were found within 1-year follow-up. CONCLUSION: Adjuvant (super-)selective infusion of 166Ho-MS after RFA for the treatment of HCC can be administered safely at a dose of 90 Gy to the treatment volume while reaching a dose of ≥ 120 Gy to the target volume and may be a favorable adjuvant therapy for HCC lesions 2-5 cm. TRIAL REGISTRATION: Clinicaltrials.gov NCT03437382 . (registered: 19-02-2018).
引用
- Hendriks P, Rietbergen DDD, van Erkel AR, et al. Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial). Eur J Nucl Med Mol Imaging. 2024. PMID: 38329507. doi:10.1007/s00259-024-06630-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。